Research.Patient.info
Relapsed or Refractory Multiple Myeloma (RRMM) research hub
2 indexed studies · 1 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Hungary · Spain · Czechia - recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
United States · Argentina · Australia